Angiopoietin-1: an early biomarker of diabetic nephropathy?

Alexandra E Butler, Ahmed Al-Qaissi, Thozhukat Sathyapalan, Stephen L Atkin, Alexandra E Butler, Ahmed Al-Qaissi, Thozhukat Sathyapalan, Stephen L Atkin

No abstract available

Keywords: Biomarkers; Diabetic kidney disease; Proteomics; Type 2 diabetes.

Conflict of interest statement

No authors have any conflict of interest or competing interests to declare.

Figures

Fig. 1

Circulatory levels of proteins protective of renal function at baseline, at hypoglycemia and at post-hypoglycemia timepoints in T2D and control subjects, and upon glucose level normalization in T2D subjects. Proteomic (Somalogic) analysis of fibroblast growth factor 20 [FGF20], angiopoietin-1 [ANGPT1] and tumor necrosis factor ligand superfamily member 12 [TNFSF12] was undertaken. A–C Blood sampling was performed at baseline (BL), at hypoglycemia (0 min) and post-hypoglycemia (30-min, 1-h, 2-h, 4-h and 24-h) for controls (white circles) and for T2D (black squares). At baseline (BL), blood glucose (BG) was 7.5 ± 0.4 mmol/L (for T2D) and 5.0 ± 0.1 mmol/L (for control, C). At point of hypoglycemia, blood glucose (BG) was 2.0 ± 0.03 mmol/L (for T2D) and 1.8 ± 0.05 mmol/L (for control). D–F Blood sampling was performed at baseline (BL) in both controls (white circles) and T2D (black squares), and at glucose normalization (BM) in T2D subjects [4.5 ± 0.1 mmol/L (81 ± 1.2 mg/dl)] for a duration of 1-h. In the control cohort, mean plasma glucose was maintained at the baseline level of 4.9 ± 0.1 mmol/L (88.2 ± 1.8 mg/dl) during this normalization period. Statistics: T2D vs control: *p < 0.05, **p < 0.01, ***p < 0.001; T2D BL vs subsequent timepoints: $p < 0.05, $$p < 0.01, $$$p < 0.001; T2D hypoglycemia vs subsequent timepoints: &p < 0.05, &&p < 0.01, &&&p < 0.001; Control BL vs subsequent timepoints: #p < 0.05; ##p < 0.01, ###p < 0.001; Control hypoglycemia vs subsequent timepoints: ^p < 0.05. ^^p < 0.01, ^^^p < 0.001. RFU: relative fluorescent unit